Association of serum platelet-to-lymphocyte ratio levels with the risk of stent thrombosis and long-term prognosis in patients undergoing percutaneous coronary intervention with and without type 2 diabetes mellitus: a large-scale prospective cohort study

2.1. Study design and population

In this prospective cohort study, 10724 patients who underwent PCI from January 2013 to December 2013 were consecutively screened. PCIs were all performed at Fuwai Hospital, Chinese Academy of Medical sciences. Adult patients (>18 years old) who were treated with drug-eluting stents (DES) implantation were eligible for this research. Exclusion criteria include a combination of hematological disorders, active tumors, infection, immune-suppressant or steroid drug application, and missing baseline data. After that, 8831 patients were ultimately enrolled in this study (Figure S1). Platelet and lymphocyte counts were collected from one blood sample before the PCI procedural, and PLR was calculated using the formula of plasma platelet count (10⁹/L) to plasma lymphocyte count (10⁹/L) ratio ¹¹. To investigate the prognostic value of PLR in CAD under different glycemic states, enrolled patients were firstly divided into two groups: PLR-Low (n=4419) and PLR-High (n=4412), and further allocated into four groups: PLR-H-T2DM (n=1263), PLR-L-T2DM (n=1404), PLR-H-Non-T2DM (n=3149), PLR-L-Non-T2DM (n=3015). The optimal PLR cut-off was defined as the median of all participants (PLR=107, interquartile range: 84.7-135.5), and T2DM was defined as a history of T2DM from the on-admission medical record, receiving oral hypoglycemic agents or insulin, fasting glucose level ≥126 mg/dL, or hemoglobin A1c (HbA1c) level ≥ 6.5%. All patients received a clinical follow-up with a median time of 2.4 years after the operation. The clinical status was evaluated at 1, 6, and 12 months in the first year after discharge, and annually assessed in the following years by telephone interview.

The research process was following the Declaration of Helsinki and was approved by the Institutional Review Board of Fuwai Hospital, Chinese Academy of Medical sciences. All subjects provided informed written consent for long-term follow-up before intervention.

2.2. Data collection and definitions

Data on variables of interest were prospectively collected in all participants, which comprised demographic data (age, sex, BMI, comorbidities, past histories, smoking or not), on-admission diagnosis, physical/imaging/laboratory examination, target lesion/vessel information, PCI procedure and medicine therapy after PCI/at discharge. Comorbidities collected in this study included diabetes mellitus, hypertension (more than twice on different days by systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg during the baseline hospitalization or known hypertension with antihypertensive medication), and dyslipidemia (plasma total cholesterol [TC] ≥ 5.2 mmol/L, triglyceride [TG] ≥ 1.7 mmol/L, low-density lipoprotein cholesterol [LDL-C] ≥ 3.4 mmol/L, high-density lipoprotein cholesterol [HDL-C] < 1.0 mmol/L, and/or known dyslipidemia receiving lipid-lowering therapy). Past histories included previous myocardial infarction (MI), revascularization (PCI/coronary artery bypass grafting [CABG]), peripheral artery disease (PAD), and stroke. Chronic coronary syndrome (CCS) or acute coronary syndrome (ACS) was diagnosed according to on-admission clinical presentation. As for coronary disease, left main artery disease (LM, ≥50% stenosis in LM coronary artery), three-vessel disease ( ≥ 50% in all three main epicardial coronary arteries), and lesion characteristics (chronic total occlusion [100% occlusion of a native coronary artery for more than 3 months with thrombolysis in myocardial infarction (TIMI) flow grade of 0], bifurcation, calcification, and syntax score [estimated using an online calculator (http://www.syntaxscore.com/)]) were recorded by two independent interventionists at Fuwai hospital. The number of the treated vessel and implanted DES during PCI and procedural success (the residual stenosis ≤ 30% and grade 3 TIMI flow without apparent dissection) or not were collected as procedural data. Medicine therapies after PCI include dual antiplatelet therapy (DAPT), GPIIb/IIIa receptor antagonists, β-blocker, statins, and nitrate.

2.3. Laboratory examination

Blood samples were collected from patients before PCI and stored in −80 °C refrigerators until the test. The process of laboratory examination was performed at the core laboratory in Fuwai hospital, according to the standard operation guideline. In this study, routine blood tests (Hgb, white blood cells [WBC], lymphocyte, platelet), lipid profiles (TG, TC, HDL-C, and LDL-C), creatinine, high-sensitivity C-reactive protein (hs-CRP) and glycosylated hemoglobin A1c (HbA1c) were presented.

2.4. Procedures

PCIs were all performed by experienced interventionalists in Fuwai hospital. Before PCI, patients all received a loading dose of DAPT (300 mg of aspirin and 300 mg of clopidogrel the day or ticagrelor 180 mg) and heparin treatment with an initial bolus of 70-100 IU/kg (before the procedure) with an additional dose of 1000 IU administered per hour (during the procedure). The access of intervention was radial or femoral artery. Angiography was performed in all participants, and the application of adjunctive examinations (intravascular ultrasound and optical coherence tomography) and devices (balloon and stent) choice depended on the operators.

2.5. Outcomes

The primary endpoints of this study were major adverse cardiovascular and cerebrovascular events (MACCE, a composite of all-cause death, MI, stroke, and target vessel revascularization [TVR]). The secondary outcomes were the individual components of MACCE and stent thrombosis. MI was diagnosed according to the third universal definition of MI ¹⁴ and TVR referred to any repeat revascularizations of the treated vessel in PCI. Stroke was defined as cerebrovascular events (ischemic or hemorrhagic) confirmed by two neurologists and stent thrombosis was defined as a thrombotic occlusion of a coronary stent (defined according to Academic Research Consortium criteria) ¹⁵. The time definitions of acute stent thrombosis (AST), subacute stent thrombosis (SAST), late stent thrombosis (LST), and very late stent thrombosis (VLST) were 0-24 hours, 24 hours to 30 days, 30 days to 1 year and longer than 1 year after stent implantation, respectively ¹⁶. The events above were all confirmed by at least two independent specialists of cardiology, and the disagreement was resolved by consulting a third experienced cardiologist.

2.6. Statistical analysis

Categorical variables were presented as “number (%)”. Continuous variables were described as “mean ± standard deviation (SD)” when they were normally distributed. Two-sample T-test was used to assess whether there was a statistical difference in continuous variables when they were normally distributed, otherwise, the Mann-Whitney U test was used. χ² test was applicated to test the differences in categorical variables, although Fisher’s exact test was used for the small sample size. Kaplan-Meier (K-M) plots and Cox proportional hazards regression models were used for survival analysis, which was based on the time from operation to primary outcomes. KM plots for PLR-L vs. PLR-H, PLR-L/T2DM vs. PLR-H/T2DM, PLR-L/ Non-T2DM vs. PLR-H/Non-T2DM and PLR-L/ Non-T2DM vs. PLR-H/Non-T2DM vs. PLR-L/T2DM vs. PLR-H/T2DM were presented, and Log-rank test was used to evaluate the statistical significance. When analyzing PLR as a continuous variable, the Log-transformation of PLR was performed (ln [platelet-to-lymphocyte ratio]). Restricted cubic spline (RCS) with 4 knots (5^th, 35^th, 65^th, and 95^th percentiles) in the fully adjusted model was used to estimate the dose-response relationship between PLR and the risk of outcomes. Nonlinearity was tested using the likelihood ratio test.

In the muti-COX regression model, PLR-L/Non-T2DM and PLR-L/ T2DM were referenced. Adjusted cofounding factors include age, male sex, body mass index (BMI), hypertension, dyslipidemia, smoking history, previous MI, previous PCI/CABG, previous stroke, previous PAD, Acute coronary syndrome (ACS), LM/three-vessel disease, chronic total occlusion (CTO), moderate to severe calcification, procedural success, number of treated vessels, number of stents, TC, LDL-C, hs-CRP, creatine, left ventricular ejection fraction (LVEF), DAPT, β blocker, and statins. The hazard ratio (HR) and 95% confidence interval (CI) were presented. Sub-group analysis was further performed in 6 different subsets (sex [male or female], age [< 65 or ≥ 65 years], BMI [<25.0 or ≥25.0 kg/m²], smoking status [never or former and current], hypertension [yes or no], and ACS [yes or no]), which was presented with a forest plot. Sensitivity analyses excluding patients who presented MACCE within the first 30 days of follow-up, did not receive DAPT and did not receive successful PCI were progressively conducted based on the fully adjusted model.

Statistically, significance was determined when two-sided α was less than 0.05. All the statistical analyses were done using the SPSS version 27.0 (IBM Corporation, Armonk, NY) and RStudio software (version 2021.09.0; http://www.rstudio.org/).

3.1. Baseline characteristics

Generally, 8831 consecutive CAD patients (58.39 ± 10.27 years, 77.0% male) who received PCI with DES implantation were included in this study. The baseline characteristics of four groups based on PLR levels and glycemic metabolism status were listed in Table 1. Compared with diabetic patients with a higher level of PLR, those in the other three groups were older and more likely to be female, with a higher prevalence of hypertension, dyslipidemia, previous revascularization, previous stroke, and previous PAD. Laboratory test results including PLR and CK-MB were significantly higher in the PLR-H/T2DM. For coronary procedural characteristics, individuals in the PLR-H/T2DM group were more likely to have a higher SYNTAX score and LM/three-vessel disease when compared with those in the other 3 groups. Besides, the comparisons in baseline characteristics between the PLR-low and PLR-high groups were also performed and presented in Table S1.

3.2. PLR levels and the risk of MACCE in the whole cohort

During a median follow-up of 2.4 years (interquartile range: 2.2-2.6 years), 101 (1.1%) all-cause deaths, 97 (1.1%) MI, 131 (1.5%) strokes, 414 (4.7%) TVR, and 663 (7.5%) MACCEs were recorded. Table 3 displayed the comparison of clinical outcomes risks between the PLR-H and PLR-L groups. In multivariable analysis after adjusting for confounding factors, the PLR-H group was at significantly higher risk of MACCE (HR: 1.26, 95%CI: 1.07 to 1.47, P = 0.005), and all-cause death (HR: 1.87, 95%CI: 1.21 to 2.89, P = 0.005). Consistently, the K-M analysis curves also revealed a higher risk of MACCE in patients with PLR-H compared with those with PLR-L (log-rank P = 0.001, Figure 1A).

• Download figure
• Open in new tab

Figure 1.

Kaplan–Meier curves for cumulative incidence of MACCE, according to different PLR levels (A), different PLR levels in non-T2DM patients (B) and T2DM patients (C), and four risk groups (PLR-L/non-T2DM, PLR-H/non-T2DM, PLR-L/T2DM and PLR-H/T2DM) (D).

PLR-L, low level of platelet to lymphocyte ratio (< 107.0); PLR-H, high level of platelet to lymphocyte ratio (≥ 107.0); T2DM, type 2 diabetes mellitus.

When analyzing PLR as a continuous variable, results showed that a per 1 unit increase in PLR-ln was associated with a 49% increase in the risk of MACCE (95%CI: 1.18 to1.87, P = 0.001) (Table S2). RCS analysis further determined a linear relationship between PLR and the risk of MACCE in the whole cohort (P for non-linearity = 0.071) (Figure S2).

3.3. PLR levels and the risk of MACCE in patients with and without T2DM

The incidence of MACCE in PLR-H with T2DM or non-T2DM and PLR-L with T2DM or non-T2DM group was 14.3% (178/1263), 10.6% (337/3149), 11.1% (158/1404), 10.6% (318/3015), respectively. Risks of MACCE were compared in four different risk groups by the Cox regression model, using the PLR-L-non-T2DM and PLR-L-DM groups as reference 1 and 2, respectively (Table 3). Compared with reference 1, patients in the PLR-H/non-T2DM were at significantly higher risk of all-cause mortality in univariable analysis (HR: 2.04, 95%CI: 1.20 to 3.47, P = 0.009), while no significant difference was presented in multivariable analysis. When it came to referencing 2, patients with PLR-H/T2DM showed a significantly higher risk of MACCE (HR: 1.62, 95%CI: 1.25 to 2.10, P < 0.001), all-cause mortality (HR: 2.56, 95%CI: 1.32 to 5.12, P = 0.006), stroke (HR: 1.90, 95%CI: 1.08 to 3.37, P = 0.027) and stent thrombosis (HR: 4.10, 95%CI: 1.77 to 9.47, P < 0.001). In multivariable analysis after adjusting for confounding factors, increased risk of MACCE (HR: 1.53, 95%CI: 1.17 to 2.00, P = 0.002), all-cause mortality (HR: 2.18, 95%CI: 1.09 to 4.37, P = 0.028) and stent thrombosis (HR: 3.79, 95%CI, 1.62 to 8.86, P = 0.002) were still significant in PLR-H/T2DM group. When it came to the continuous analysis, with PLR-Ln increasing per 1 unit, the risk of MACCE and stent thrombosis increased by 99% (95%CI: 1.37 to 2.89, P < 0.001) in the T2DM cohort with great significance (Table S2). However, this significant association was not found in the non-T2DM cohort.

3.4. PLR levels and the risk of stent thrombosis

During the follow-up, there were 75 (0.85%) cases of stent thrombosis were recorded. In the whole cohort study, K-M plots showed that patients in the PLR-H group presented a significantly higher risk of stent thrombosis compared with patients in PLR-L (Figure 2A). This phenomenon was still significant in a patient with T2DM, but not remarkable in patients with non-T2DM (Figure 2B, C), and patients with both PLR-H and T2DM held the highest risk (Figure 2D). In Cox regression analyses, the risk of stent thrombosis was significantly higher in the PLR-High group when compared with the PLR-Low group in the T2DM cohort (Table 3). When it came to the continuous analysis, the risk of stent thrombosis increased significantly with the increase in PLR-Ln levels in the T2DM cohort (Table S2).

• Download figure
• Open in new tab

Figure 2.

Kaplan–Meier curves for cumulative incidence of stent thrombosis, according to different PLR levels (A), and four risk groups (PLR-L/non-T2DM, PLR-H/non-T2DM, PLR-L/T2DM and PLR-H/T2DM) (D).

PLR-L, low level of platelet to lymphocyte ratio (< 107.0); PLR-H, high level of platelet to lymphocyte ratio (≥ 107.0); T2DM, type 2 diabetes mellitus.

We further performed the adjusted Cox regression model for the subtypes of stent thrombosis in the whole cohort and DM cohort (Table S3). Results showed that VLST occupied the largest proportion (52%) and was the only subtype whose risk was significantly positively associated with the PLR-Ln levels in T2DM (HR 2.04, 95%CI: 1.34 to 5.64, P = 0.008).

3.5. Subgroup and sensitivity analysis

Subgroup analysis was performed to evaluate the association of risk groups and MACCE and stent thrombosis across different subgroups, including age, sex, BMI, hypertension, smoking status, and ACS (Figure S3, Figure S4, and Table S4, S5). There was a significant interaction between risk groups and MACCE and stent thrombosis by age of 65 years (P for interaction = 0.002 and 0.031, respectively), whereas the consistent association of risk groups with MACCE risk was observed in patients with different sex, BMI, hypertension-status, smoking-status and clinical presentation (P for interaction > 0.05) after multiple adjustments. Sensitivity analysis for excluding patients who presented MACCE within the first 30 days of follow-up, received unsuccessful PCI, and did not receive DAPT was further performed with the outcomes of MACCE and stent thrombosis, and no change in conclusions was found in three cohorts (Table S6). Sensitivity analysis for individuals of MACCE was presented in Table S7-S9.